Macrophages show endoplasmic reticulum (ER) stress when exposed to lipotoxic signals associated with atherosclerosis, although the pathophysiological importance and the underlying mechanisms of this phenomenon remain unknown. Here we show that mitigation of ER stress with a chemical chaperone results in marked protection against lipotoxic death in macrophages and prevents macrophage fatty acid-binding protein-4 (aP2) expression. Using genetic and chemical models, we show that aP2 is the predominant regulator of lipid-induced macrophage ER stress. The absence of lipid chaperones incites an increase in the production of phospholipids rich in monounsaturated fatty acids and bioactive lipids that render macrophages resistant to lipid-induced ER stress. Furthermore, the impact of aP2 on macrophage lipid metabolism and the ER stress response is mediated by upregulation of key lipogenic enzymes by the liver X receptor. Our results demonstrate the central role for lipid chaperones in regulating ER homeostasis in macrophages in atherosclerosis and show that ER responses can be modified, genetically or chemically, to protect the organism against the deleterious effects of hyperlipidemia.
Macrophages show endoplasmic reticulum (ER) stress when exposed to lipotoxic signals associated with atherosclerosis, although the pathophysiological importance and the underlying mechanisms of this phenomenon remain unknown. Here we show that mitigation of ER stress with a chemical chaperone results in marked protection against lipotoxic death in macrophages and prevents macrophage fatty acid-binding protein-4 (aP2) expression. Using genetic and chemical models, we show that aP2 is the predominant regulator of lipid-induced macrophage ER stress. The absence of lipid chaperones incites an increase in the production of phospholipids rich in monounsaturated fatty acids and bioactive lipids that render macrophages resistant to lipid-induced ER stress. Furthermore, the impact of aP2 on macrophage lipid metabolism and the ER stress response is mediated by upregulation of key lipogenic enzymes by the liver X receptor. Our results demonstrate the central role for lipid chaperones in regulating ER homeostasis in macrophages in atherosclerosis and show that ER responses can be modified, genetically or chemically, to protect the organism against the deleterious effects of hyperlipidemia.
Organelle-mediated stress, particularly endoplasmic reticulum (ER) stress,
has recently emerged as an important pathophysiological paradigm underlying chronic
metabolic diseases1–8. In conjunction with its central role in
protein synthesis, folding and transportation, the ER serves as a critical site for
integrating cellular responses to stress9. The
presence of misfolded proteins and other stresses lead to the activation of an
adaptive program by the ER, known as the unfolded protein response (UPR), to
reestablish equilibrium9. Initiation of the
canonical UPR engages three distinct signaling branches mediated by pancreatic ER
kinase (PERK), inositol-requiring transmembrane kinase/endonuclease 1 (IRE1) and
activating transcription factor 6 (ATF6). The UPR is also linked to the activation
of stress kinases such as the c-Jun N-terminal kinase (JNK). The combined action of
these pathways leads to inhibition of protein translation, stimulation of protein
degradation, and the production of chaperone proteins resulting in either recovery
of ER function or cell death10.In obesity, activation of the UPR in metabolic tissue contributes to insulin
resistance, at least in part through IRE-1-dependent, JNK-1-mediated inhibition of
insulin action5. Promotion of ER stress by
genetic X-box binding protein 1 (XBP-1) haploinsufficiency, which functions in the
UPR-induced transcriptional program, also leads to systemic insulin resistance,
while alleviation of ER stress by chemical or molecular chaperones protects mice
against insulin resistance and type 2 diabetes5–7. Activation of ER
stress response pathways is also a characteristic of lipid-laden macrophages in
atherosclerotic lesions in mice and humans and is proposed to play a role in plaque
vulnerability and acute cardiac death3,4,8.
However, the role of ER stress in macrophages and cardiovascular disease remains
obscure and it is unknown whether the modulation of ER stress pathways could alter
the function and survival of macrophages and the course of atherosclerosis.
Moreover, it is unclear how accumulation of excess lipids in macrophages can engage
the ER stress response pathways. Despite continuing debate, it is likely that the
biological effects of toxic lipids such as those prevalent in dyslipidemia are
signaled through specific pathways rather than lipotoxicity representing a
non-specific demise of cellular function and viability. Several pieces of evidence
suggest a connection between lipid metabolism and the UPR. For example, XBP-1 plays
a role in ER phosphatidylcholine synthesis and endomembrane expansion, and has been
linked to transcriptional regulation of several lipogenic genes in the liver11,12.
ER stress can induce lipogenesis and promote hepatic steatosis12–15. On
the other hand, inhibition of phospholipid synthesis or increasing phospholipase
activity exacerbates ER stress responses and sphingolipid levels can influence ER
function16,17. Additionally, ER stress was identified as a mechanism
driving free cholesterol-induced cell death, in a model of cholesterol loading3. Hence, it is possible that the ER may serve
as an important target organelle that senses stresses related to lipid status and
exposure10. However, the signaling
networks linking ER function, lipid metabolism and the physiological outcomes are
not known.Cellular lipid metabolism and reception of lipid signals are regulated by
cytosolic lipid chaperones, particularly fatty acid binding protein-4 (aP2), which
exhibit profound effects on chronic metabolic diseases and whose function is
relevant to human disease10,18,19–23. The dramatic
impact of aP2 on atherosclerosis is related exclusively to its action in the
macrophages although the underlying mechanisms are not fully resolved22. The fact that macrophage aP2-deficiency can
mediate protection from atherosclerosis in the setting of severe dyslipidemia raised
the possibility that lipid chaperones may be a link between toxic lipids and
organelle stress in macrophages.Here, we explored the mechanisms related to lipotoxic macrophage ER stress
and the impact of ER dysfunction on atherosclerosis utilizing a chemical chaperone
and lipid chaperone-deficient mouse model. We demonstrate that mitigation of ER
stress is protective against atherosclerosis and that aP2 is an obligatory
intermediate for macrophage ER stress responses to lipids.
RESULTS
I: Blocking macrophage ER stress and atherosclerosis
The chemical chaperone, 4-phenyl butyric acid (PBA) can alleviate ER
stress, and hence, provides an experimental opportunity to approach the role of
ER stress in atherosclerosis7,24. We first tested whether PBA can alter
ER stress induced in macrophages upon exposure to saturated fatty acids25,26. Treatment with palmitate (PA) induced ER stress in macrophages as
determined by phosphorylation of PERK (P-PERK) and eukaryotic translation
initiation factor 2α (P-eIF2–α). However,
co-treatment with PBA resulted in essentially complete protection against
PA-induced ER stress (Fig.1a). PBA
treatment also suppressed PA-induced splicing of XBP-1 (sXBP-1) and C/EBP
homologous protein (CHOP) expression, two elements of the UPR-induced
transcriptional program (Fig.1b,c). Since
saturated fatty acids or modified lipoproteins can induce apoptotic pathways we
next asked whether modifying ER stress in this setting could prevent lipotoxic
death in macrophages27. Treatment with
PBA resulted in marked protection against PA-induced apoptosis in macrophages,
as determined by TUNEL assays (Fig.1d and
Supplementary
Fig.1a). These results demonstrate that PBA can protect cultured
macrophages against lipid-induced ER stress and apoptosis in
vitro.
Figure 1
PBA treatment protects against macrophage ER stress and reduces vascular
disease progression
(a–d) We induced ER stress in WT
macrophages by 500 µM PA or 300 nM thapsigargin (Thaps) in the
presence or absence of 3 mM PBA. P-PERK and P-eIF2–α
were examined by Western blotting (a), mRNA levels of
Ddit3
(b) and sXBP-1 were examined by qRT-PCR
(c), and apoptosis were examined by TUNEL assays
(d) (data represent mean±SEM; *
p<0.05). (e–g) Atherosclerotic lesion
area in the aortic sinus from mice treated with either control or PBA for 2
weeks (n≥13) is reported (data represents mean±SD; *
indicates p<0.05) (e) and the serial sections were
stained with antibodies against P-PERK (f),
P-eIF2–α (f), ATF3 (g) and
MOMA-2 (f,g) (Red indicates positive staining with antibody.
Scale bars represent 200 µm). (g) Relative
fluorescent intensity was calculated for antibody staining corresponding to
ATF3 and P- eIF2–α expression (n≥3) in
the macrophage-dense areas (data represent mean±SD; * indicates
p<0.05). (h) Percent of apoptotic cells (TUNEL
positive) in the aortic sinus area are shown for PBS (control) or 100 mg
kg−1 PBA (PBA-100) treated mice (Arrows point to
apoptotic cells. Scale bars represent 200 µm. *indicates
p<0.05).
Next, to elucidate whether PBA could mitigate ER stress in
atherosclerotic lesions in vivo, we analyzed ER stress
indicators and apoptosis in serial sections from aortic sinuses of
atheroscleroticmice briefly treated with PBA. Six-week-old, male,
ApoEmice were
fed with a Western diet for 8 weeks, and given daily doses (10 mg
kg−1 or 100 mg kg−1) of PBA or
vehicle during the final 2 weeks. Examination of the sections of the aortic
sinus for proximal lesions demonstrated that
ApoEmice
receiving PBA showed a dose-dependent reduction (9%, NS and
32%, p<0.05, respectively) in atherosclerosis (Fig.1e). At this early stage of
atherosclerosis, en face analysis was similar between the
groups (Supplementary
Fig.1b). Of note, suppression of macrophage ER stress and reduction in
vascular lesions by PBA treatment occurred in the absence of any impact on
lipids, lipoprotein profiles, glucose and insulin levels in the circulation and
body weight (30.6±0.4g vs. 29.5±0.6g; p=0.19) (Supplementary
Fig.1c–f and data not shown). Hence, this relatively
short treatment period provided a suitable experimental design to examine the
status of ER stress indicators and apoptosis in atherosclerotic lesions without
significant changes in systemic metabolic parameters, insulin sensitivity or
dramatic alterations in total burden of lesions that occurs with longer PBA
treatment (data not shown)7,24. Immunohistochemical analysis revealed
that all mice developed early lesions that predominantly contained macrophages
and macrophage-derived foam cells (shown by staining with
monocyte/macrophage-specific antibody, MOMA-2) (Fig.1f). There was no significant reduction in total macrophage area
upon PBA treatment despite reduction in lesion size (macrophage area in control:
123097±13711 and in PBA treatment:
170545±30249µm2). The atherosclerotic
lesions of ApoE (control)
mice stained positive for the ER stress markers,
P-eIF2–α and P-PERK in macrophage dense areas (Fig.1f). In contrast,
P-eIF2–α and P-PERK staining was significantly
diminished in atherosclerotic lesions of mice treated with PBA (Fig.1f). Immunofluorescent staining revealed
a 44% reduction in ATF3 expression (p<0.05) and a
53% reduction in P-eIF2–α expression
(p<0.05) in the macrophage-dense areas of the lesions following PBA
treatment (Fig.1g and Supplementary Fig.1g). We
also examined the extent of apoptosis in these atherosclerotic lesions using
TUNEL staining. Atherosclerotic lesions from control mice contained abundant
apoptotic cells whereas lesions from PBA treated mice exhibited significant
reduction in apoptotic cells in a dose dependent manner (29% and
42%, respectively; p<0.05 in the 100 mg
kg−1 dose) (Fig.1h). These results demonstrate that PBA treatment leads to marked
reduction in macrophage ER stress and apoptosis in atherosclerotic lesions
in vivo indicating that improvement of ER chaperoning
function can protect against the deleterious effects of toxic lipids in
promoting atherosclerotic lesions.
II: Regulation of lipid-induced ER stress by a lipid chaperone
It has been shown that aP2-deficiency in macrophages protects against
atherosclerosis despite a highly unfavorable lipid profile22,28,29. Since, toxic lipids fail to trigger ER
stress in the presence of PBA, we investigated whether lipid chaperoning
activity is linked to ER stress and PBA activity in macrophages. Notably, aP2
immunostaining was significantly suppressed in vascular lesions of
ApoEmice treated
with PBA when compared to vehicle treated animals (71%,
p<0.05) (Fig.2a,b).
Furthermore, PA induced rapid and marked upregulation of aP2 protein, but not
aP2 mRNA levels (Fig.2c). Induction of aP2 by PA was prevented upon co-treatment with PBA
(Fig.2c). Taken together, these results
indicate that aP2 expression is directly related to lipid-induced ER stress and
strongly inhibited by PBA in macrophages in vitro and
in vivo. This observation led us to ask whether aP2
regulates ER responses to lipid stress in macrophages. Treatment of wild type
(WT) macrophages with long-chain saturated fatty acids such as PA or stearate
(STE), but not their monounsaturated counterparts, led to ER stress as judged by
the robust phosphorylation of PERK and eIF2–α,
activation of JNK, and induction Ddit3 and
sXBP-1 expression (Fig.2d,e and Supplementary Fig.2b,d and g). However, PA failed to induce ER
stress in aP2-deficient
(aP2) macrophages (Fig.2d,e and Supplementary Fig.2g). In
these cell lines, there were no alterations in PA uptake (Supplementary Fig.2e).
The aP2 cells also
maintained the ability to respond to tunicamycin, an inhibitor of protein
glycosylation that leads to ER stress, indicating that they do not suffer from a
general defect in mounting ER stress responses (Fig.2d,e).
Figure 2
Requirement for aP2 in lipid-induced ER stress and apoptosis
(a–b) Serial sections from aortic sinus of
PBS or PBA treated
ApoE mice were
stained for antibodies against MOMA-2 or aP2 (Arrows point to red staining
for these antibodies in macrophage-dense areas. Scale bar represents 200
µm) (b) Relative fluorescence intensity for aP2
expression (green) in the macrophage-dense areas (red) of the lesions was
calculated (Scale bar represents 100 µm. Data represent
mean±SD; * indicates p<0.05 and n≥3).
(c) aP2 expression was determined by Western blotting in PA
(500 µM) treated macrophages in the presence or absence of 3
µM PBA or 100 µg mL−1
cycloheximide (CHX). (d) P-PERK,
P-eIF2–α was examined by Western blotting and JNK
activity (P-cJun) by an in vitro kinase assay from PA (500
µM) treated macorphages. (e) sXBP-1 was examined by
qRT-PCR in (500 µM) PA- or (2 µg/mL) tunicamycin
(Tunic) treated (12 h) macrophages. (f) Cleaved PARP and
tubulin expression were examined by Western blotting in PA-treated (24 h)
macrophages (relative band intensities were quantified and data represent
mean±SEM; *p<0.05). (g) P-PERK,
P-eIF2–α were examined by Western blotting, JNK
activity (P-c-Jun) by a kinase assay, and sXBP-1 by RT-PCR
from macrophages treated with 10 µM ACAT inhibitor (Ai) and 100
µg/mL Ac-LDL (24 hours) or 300 nM thapsgiargin (Thaps) (The
ratio of relative intensities corresponding to spliced
(s-XBP1) and unspliced (u-XBP1) were
calculated).
We then compared ER stress responses in
aP2 macrophages
reconstituted with a lipid-binding mutant (LM) of aP2 (R126L, Y128F;
aP2LM) to those
reconstituted with WT aP2
(aP2REC)30. Under the conditions tested, WT- and
LM-aP2 proteins were expressed at comparable levels to each other and did not
lead to any alterations in lipid uptake (Supplementary Fig.2e and data not shown). Reconstitution of
WT-aP2 rendered aP2
macrophages responsive to PA as indicated by the induction of P-PERK,
P-eIF2–α and JNK activity, while
aP2LM macrophages
remained markedly resistant to PA-induced ER stress (Fig.2d). PA also induced the expression of
Ddit3 and sXBP-1 in WT but not in
aP2 macrophages
(Supplementary
Fig.2g and Fig.2e). In
aP2 macrophages,
reconstitution of aP2 restored the induction of UPR target genes by PA (Fig.2d,e and Supplementary Fig.2g).
Consistent with their ER stress-resistant phenotype,
aP2 macrophages
were also significantly protected against PA-induced apoptosis as indicated by
suppression of caspase-3 activity and PARP cleavage (Fig.2f and Supplementary Fig.2h). Reconstitution of WT-aP2 into the
aP2 macrophages
rendered these cells susceptible to lipid-induced apoptosis whereas cells
expressing LM-aP2 remained refractory to apoptosis, demonstrating the
requirement for the lipid binding activity of aP2 in regulating ER stress
responses (Fig.2f and Supplementary Fig.2h).Next, we exposed macrophages to free cholesterol (FC) loading in order
to examine ER stress responses in another setting of lipotoxicity associated
with the pathogenesis of atherosclerosis4.
In WT, but not aP2
macrophages, FC induced ER stress as indicated by the induction of P-PERK and
P-eIF2–α, sXBP-1, and JNK activity (Fig.2g). These observations were also independent of
compromised cholesterol uptake; in fact,
aP2 macrophages
exhibit increased cholesterol influx31.
Responsiveness to FC-induced ER stress was restored in
aP2 macrophages,
upon reconstitution of aP2, demonstrating that aP2 mediates FC-induced ER stress
in macrophages (Fig.2g). Furthermore,
aP2 macrophages
were resistant to FC-induced induced apoptosis, determined by activation of
caspase 3 and cleavage of PARP, that normally occurs in FC-treated WT
macrophages (Supplementary
Fig.2i)3. Taken together our
results show that aP2 is necessary for toxic lipids to trigger ER stress and
apoptosis in macrophages.
III: Regulation of macrophage ER stress by aP2 in vivo
We next investigated whether aP2-deficiency in mice can modulate ER
stress responses in vascular lesions in vivo. The
aP2mouse model
provides an ideal setting to examine the link between macrophage ER stress and
atherosclerosis since aP2-deficiency does not alter the hyperlipidemia or any
other metabolic parameters in the
ApoE background, and
furthermore, aP2’s impact on atherosclerosis is predominantly, if
not completely, mediated by its action in the macrophages22. The early stage atherosclerotic plaques from
ApoEmice showed
induction of ER stress as indicated by elevated P-PERK,
P-eIF2–α, and Ddit3 mRNA in the
infiltrating macrophages within the lesions (Fig.3a). Notably, the vascular lesions in the
aP2mice were
essentially devoid of staining for markers of ER stress (Fig.3a). Quantitative analysis of ER stress by
immunofluorescent staining demonstrated a significant reduction in
P-eIF2–α and ATF3 (55% and 67%,
respectively; p<0.05) expression in macrophage-rich areas of the
lesions (Fig.3b,c). Furthermore, TUNEL
assays demonstrated a significant reduction in the number of apoptotic
macrophages in lesions of
aP2mice compared to ApoE
animals (7.8% and 18.4%, respectively;
p<0.05) (Fig.3d,e and Supplementary Fig.3a).
This confirmed the critical role of aP2 in mediating macrophage ER stress
response to toxic lipids in vivo, similar to its actions in
cultured macrophages in vitro.
Figure 3
aP2 deficiency protects from hypercholesteremia induced macrophage ER
stress and apoptosis in atherosclerotic lesions
(a–b) Immunohistochemical staining with
antibodies against MOMA-2, P-PERK, P-eIF2–α
(a,b), CHOP (a), and ATF3 (b)
were performed in atherosclerotic lesions from the proximal aorta of
ApoE and
aP2
mice fed a Western diet for 16 weeks (Arrows point to ATF3 and
P-eIF2–α (green), expressed in the MOMA-2 positive
(red) areas of the lesions. Scale bars in (a) represent 50 µm
and in (b) represent 100 µm). (c) Relative
fluorescent intensity was calculated for stainings corresponding to ATF3 and
P-eIF2–α in the macrophage-dense areas (data
represent mean±SD; * indicates p<0.05,
n≥3). (d–e) Apoptotic macrophages in
the lesions from ApoE
and
aP2
mice were determined by TUNEL assay (Arrows point to apoptotic cells. Scale
bars represent 100 µm. * indicates p<0.05).
(f–g) Macrophage lines were stressed with PA
(500 µM) in the presence of vehicle (−) or varying
does of the aP2-i (0.1–50 µM). P-PERK and
P-eIF2–α was examined by Western blotting
(f) and sXBP-1 and Ddit3 mRNA
were analyzed by qRT-PCR from macrophages treated with 25 µM of
aP2-i (g). (h) Double immunofluorescent staining was performed
using antibodies against MOMA-2 and ATF-3 in the atherosclerotic lesions
from ApoE mice
treated with vehicle or aP2-i (15 mg kg−1 for 14
weeks) (Arrows indicate staining for ATF3 (green) in MOMA-2 positive areas
(red). Scale bars represent 100µm).
The impact of genetic aP2-deficiency can be mimicked by a specific
chemical inhibitor for aP2 (aP2-i) in vitro and in
vivo29. Treatment of WT
macrophages with aP2-i also led to marked protection against PA-induced ER
stress as assessed by diminished P-PERK, P-eIF2–α,
Ddit3 and sXBP-1 expression, without any
effects on fatty acid uptake (Fig.3f,g and
Supplementary
Fig.3b). Treatment with aP2-i also reduced ATF3 expression in
macrophage-dense areas of the plaques in
ApoEmice
in vivo, without altering hyperlipidemia (Fig.3h)29. These results clearly demonstrate that genetic or chemical ablation
of aP2 protects macrophages from ER stress in vivo in the
context of hypercholesterolemic atherosclerosis.
IV: Mechanisms linking aP2 to macrophage ER stress
In order to identify the metabolic pathways that control the observed
tolerance to toxic lipids, we next studied the impact of aP2 on macrophage lipid
composition and metabolism. We analyzed the profiles of individual fatty acids
(FA) in macrophages in a systematic manner using high resolution, quantitative
lipidomic analysis. aP2
macrophages contained elevated levels of monounsaturated fatty acids (MUFA),
indicating that a greater proportion of the lipids in these cells were produced
de novo (Supplementary Table 1). Furthermore, we saw evidence of increased
delta 9 desaturase/steaoryl CoA desaturase (Δ9D/SCD) activity in
aP2 macrophages,
reflected in the elevated C16:1n7/C16:0; C14:1n5/C14:0, and C18:1n9/C18:0 ratios
of FA present in various lipid classes (Fig.4a and Supplementary Table 1). Enhancement of de novo
lipogenesis in aP2
macrophages resulted in marked increase in C16:1n7 levels and its direct
elongation product, C18:1n7 in addition to a modest elevation in C14:1n5 and
C18:1n9 (Fig.4b and Supplementary Table 1).
The reconstitution of aP2 dramatically shifted the FA profile from one of active
de novo synthesis, with enhanced desaturase activity, to
high elongase activity with little desaturase action, demonstrating that
macrophage de novo lipogenesis is strongly regulated by aP2
(Fig.4a,b and Fig.5a).
Figure 4
Regulation of macrophage lipid composition by aP2
(a) Lipid class composition analysis for TG, PL and FA
was performed. The F statistics from one-way ANOVA are displayed as red
diamonds over the distribution of F statistics from permuted data. The black
line is the 95th percentile of the F statistics over 1000
permutations. The higher the value of the F-statistics from ANOVA, the more
different the groups are. The heat map displays the observed data, centered
to the mean of the WT genotype and scaled by the standard deviation of all
observations. (b) The mean concentration of C16:1n7 and C18:1n7
was determined for each lipid class in the various macrophage lines.
(c–d) Total lipid composition: Percent total
lipids (c) and bar plots of the mean concentration of lipids
(d) in the macrophage lines.
Figure 5
A central role for SCD and C16:1n7 in aP2 mediated lipotoxic signaling
(A) A summary of the lipid changes that occur as a
result of aP2 deficiency in macrophages (LCE and ELOVL; fatty acid elongase
for long chain fatty acid). (b)SCD-1 mRNA
levels were examined by qRT-PCR in primary peritoneal macrophages at the
base line or (c) after treatment of animals aP2-i for 6 weeks
(n=6) (data represent mean±SEM; * indicates p<0.05).
(d–e) ER stress was induced in macrophages by
PA (300 µM) or tunicamycin (2 mM) treatment for 3 hours. Cells
were pretreated with PAO (300 µM) PAO, where indicated. P-PERK,
P-eIF2–α and cleaved PARP were examined by Western
blotting (d) and Ddit3 and
sXBP-1 mRNA were examined by qRT-PCR (E). (F)
From macrophage lines treated with SCD-1 siRNA (50–100 nM) or
scrambled (−) siRNA, SCD activity (upper panel) was examined by
an enzymatic assay and SCD protein expression (lower panel) was examined by
Western blotting (G) P-PERK, P-eIF2–α
and cleaved PARP were examined by Western blotting from lysates of
aP2
macrophages treated with negative (−) siRNA or SCD-1 specific
siRNA (100nM) and treated with or without PA (500 µM) (data
represent mean±; SEM; * indicates p<0.05).
We next asked which lipid classes are enriched by these newly
synthesized fatty acids and determined the distribution of all major classes of
lipids. When compared to WT macrophages,
aP2 macrophages
had elevated phospholipids (PL;%138), triglycerides
(TG;140%), diacylglycerol (DG;143%) and free fatty acid
(FFA;224%) concentrations and lower levels of cholesterol esters
(CE;79%) (Fig.4c,d).
Reconstitution of aP2 suppressed PL levels by 31% and dramatically
increased CE concentrations by 197%, demonstrating a crucial role
for aP2 in the regulation of macrophage phospholipid and cholesterol production
(Fig.4c,d). The marked increase in the
phospholipid-to-cholesterolratio seen in the
aP2 macrophages
suggests that one potential way aP2 can modulate stress responses to toxic
lipids may be through alteration in membrane lipid composition and metabolic
properties.The results of lipidomic analysis implicated regulation of de
novo lipogenesis and desaturation, a rate-limiting step catalyzed
by SCD, as a potential mechanism underlying the aP2-driven compositional changes
in macrophages (Fig.5a). The desaturase
activity of SCD converts saturated FA to MUFA which are then incorporated into
phospholipids, triglycerides, and cholesterol esters32,33. Indeed,
aP2 macrophages
are enriched with MUFA, most significantly in C16:1n7-palmitoleate and its
direct elongation product, C18:1n7, across all major lipid classes (Fig.4b and Supplementary Table 1).
Consistently, SCD-1 expression in
aP2 macrophages was
~50 fold-higher than that of WT controls (Fig.5b). Next, we examined aP2-regulated SCD-1 expression in
macrophages in vivo and found that its expression was markedly
upregulated in the peritoneal macrophages isolated from mice treated with aP2-i
(Fig.5c). Fatty acid synthase (Fasn)
expression was also significantly elevated in
aP2 macrophages
and induced upon aP2-i treatment in vivo (data not shown).
Collectively, these data indicate that aP2 action in macrophages is linked to
the regulation of key enzymes involved in the de novo synthesis
and desaturation of fatty acids.To examine the impact of aP2-regulated SCD-1 activity in the resistance
to ER stress in aP2
macrophages, we took two distinct but related approaches. First, we asked
whether C16:1n7-palmitoleate, a product of de novo lipogenesis
elevated in aP2
macrophages, could modify ER responses to lipids34. Strikingly, we found that WT macrophages pre-treated with
C16:1n7-palmitoleate became resistant to PA-induced ER stress and apoptosis, but
not to tunicamycin-induced ER stress, determined by the
P-PERK, P-eIF2–α, cleaved PARP and
Ddit3 and sXBP-1 levels. This pattern induced
by C16:1n7-palmitoleate was highly reminiscent of genetic or chemical
aP2-deficiency (Fig.5d,e). Oleate, another
FA product of desaturation, which is not regulated to the same extent as
palmitoleate in aP2
macrophages, could also protect against PA or STE- induced ER stress (Supplementary
Fig.2b–d).Second, we utilized a siRNA-mediated approach to significantly deplete
SCD-1 protein and activity in
aP2 macrophages (Fig.5f). Sensitivity to PA-induced ER stress
and apoptosis was re-established in the SCD-1 siRNA treated
aP2 macrophages,
but not in scrambled (control) siRNA treated cells, as evidenced by increased
P-PERK and P-eIF2–α, active caspase 3 and cleaved PARP
levels (Fig.5g). These results demonstrate
that aP2-mediated regulation of SCD-1 activity is causally linked to
lipid-induced ER stress responses in macrophages.Unraveling the molecular mechanisms by which aP2 regulates SCD-1 is
important for understanding how lipid-stress signals impinge on the lipid
synthetic pathways. Both SCD-1 and Fasn are
direct transcriptional targets of the nuclear receptor LXR (LXR-responsive
elements, LXRE, are located on Fasn, between positions
−669 and −665, and SCD-1, between
positions −1263 and −1248) (Fig.6a)35,36. Thus, we analyzed whether LXR activity
is altered in aP2-deficient macrophages by utilizing an LXRE-driven reporter.
The aP2 macrophages
displayed a significant elevation in stimulated LXR activity when compared to
control, aP2REC cells
(Fig.6b). These results indicate that
aP2 negatively regulates LXR activity in WT macrophages. Consistently, we
observed increased expression of LXR target genes Abca1, Abcg1
and CD51 (AIM) in
aP2 macrophages
(Supplementary
Fig.4a–c)37–39. Further
examination revealed marked elevation of Nr1h3
(LXR–α) mRNA and protein levels in the absence of aP2,
while Nr1h2 (LXR–β) expression remained
unchanged between the genotypes (Fig.6c and
Supplementary
Fig.4d,e). Hence, the LXR–α expression appeared
to be the main driver of the alterations seen in LXR target gene expression. In
order to definitively link LXR–α activity to
SCD-1 regulation, we next suppressed Nr1h3
expression in aP2
macrophages using a siRNA-mediated knock down approach (Supplementary Fig.5a).
Reduction of Nr1h3 expression had only a partial effect on the
expression genes regulated by both LXR–α and
–β, such as Abca1 and
Abcg1, but generated a profound effect on the expression of an
LXR–α exclusive target gene, CD51 (AIM)
(Supplementary
Fig.5b–d)37–39. The
reduction in LXR–α also led to significant inhibition of
both Fasn and SCD-1 mRNA levels, demonstrating
that LXR–α is mainly responsible for the upregulation of
these genes in the absence of aP2 (Fig.6d
and Supplementary
Fig.5e). Suppression of LXR–α also restored
sensitivity to PA-induced ER stress and apoptosis as determined by induction of
P-PERK and P-eIF2–α and cleaved PARP levels in
aP2 macrophages
(Fig.6e). To validate these links in a
genetic setting, we examined lipid-induced ER stress response in primary
peritoneal macrophages derived from mice with aP2 and
Nr1h3 combined genetic deficiency. The expression of
Fasn and SCD-1 was also markedly
down-regulated in
aP2
macrophages compared to
aP2 cells (Supplementary
Fig.6b,c)40. The expression of
CD51 was profoundly suppressed in double mutant cells, while
Abca1 and Abcg1 were only partially affected
(Supplementary
Fig.6d–f)37–39.
Consequently, the protection against PA-induced ER stress was also lost in the
aP2
cells as determined by P-PERK, P-eIF2–α and cleaved PARP
induction (Fig.6f). Consistently, treatment
of WT macrophages with a specific LXR agonist, T0901317, promoted resistance to
lipid-induced ER stress, similar to aP2-deficiency (Supplementary Fig.5f).
These results illustrate that LXR–α is responsible for
the upregulation of SCD-1 in the absence of aP2 and provides one crucial
mechanism for how lipid stress signals may impinge on macrophage lipid
metabolism and ER stress (Fig.6g).
Figure 6
Linking toxic lipids to ER stress and atherosclerosis through
aP2-LXR–α crosstalk
(a) Alignment of LXR responsive element (LXRE) on
Fasn and SCD-1 promoters.
(b) LXR–driven transcriptional activity was
determined from various macrophage lines upon stimulation with a synthetic
T0901317 (10 µM) or endogenous 25-hydroxycholesterol (10
µM) LXR ligand (luciferase activity is reported after
normalizing to transfection efficiency). (c) Relative
LXR–α and LXR–β protein
levels in various macrophage lines were examined by Western blotting
(d) Relative SCD-1 and Fasn mRNA levels
from aP2 macrophage
treated with a scrambled (−) or Nr1h3-specific
siRNA were examined by qRT-PCR. (e) Lysates from various
macrophages treated with scrambled (−) siRNA or a specific siRNA
against SCD-1 or Nr1h3 and stressed with
or without PA (500 µM) were examined for P-PERK and
P-eIF2–α by Western blotting. (f)
Lysates from peritoneal macrophages from
aP2
or WT mice stressed with or without PA (500 µM) were examined
for P-PERK, P-eIF2–α and cleaved PARP by Western
blotting. (g)
A cellular lipotoxicity model: Toxic levels of lipids are
sensed by the ER through an aP2-dependent pathway and induce the UPR and
lead to macrophage apoptosis. The absence of aP2 serves to reactivate
macrophage de novo lipogenesis pathways and promotes
desaturation, particularly through LXRα-mediated activation of
SCD-1, leading to increased production of bioactive lipids and resistance to
ER stress. Our findings indicate that alleviation of macrophage ER stress,
either through aP2 inhibition or enhancing ER function, is protective
against atherosclerosis.
DISCUSSION
Macrophages are particularly vulnerable to lipid-induced toxicity and
contribute to the pathogenesis of several metabolic derangements where exposure to
lipids is increased, such as the foam cells in hypercholesterolemic atherosclerosis
and in adipose tissue-associated macrophages in obesity2,10,41. Previous studies have shown expression of
UPR markers in macrophages infiltrating the atherosclerotic lesions of both mice and
humans4,8. These findings are complemented by in vitro studies
demonstrating that accumulation of free cholesterol leads to apoptosis via
activation of ER stress in macrophages3.
Elevation of ER stress-associated macrophage apoptosis has been proposed to
contribute to advanced atherosclerotic lesions in macrophages defective in insulin
signaling42. While these findings have
sparked interest, demonstration of a link between macrophage ER stress and
atherogenesis in vivo and the mechanisms integrating lipid signals
to ER function in macrophages has been challenging. Hence, modulation of ER stress,
especially upstream of the apoptotic execution pathways, becomes critical in
understanding the extent of its contribution to the pathogenesis of atherosclerosis.
The data presented in this paper provide insight into these critical questions.
First, we demonstrate that the lipid chaperone aP2 is an obligatory mediator
coupling toxic lipids to ER stress in macrophages in vitro and
in vivo. Second, we show that alleviating ER stress, either by
the use of a chemical chaperone or through the inhibition of a lipid chaperone,
provides significant protection against macrophage ER stress, cell death, and
atherosclerosis.The surprising and striking upregulation of aP2 by saturated fatty acids and
downregulation by PBA in macrophages led to the uncovering of a previously unknown
function of the lipid chaperones in mitigating ER stress in macrophages in
vitro and in atherosclerotic lesions in vivo. The
observations place aP2 as a central modulator of lipid—induced ER stress
responses—a process for which there had been previously little
mechanistic insight. It is also established that the role of macrophage aP2 action
on atherosclerosis is not related to other metabolic alterations, such as changes in
insulin sensitivity or dyslipidemia, and is therefore intrinsic to macrophages22,43.
Similarly, the treatment with PBA dose used in this study, and as reported earlier,
does not yield significant metabolic alterations7. Therefore, our present findings unravel a mechanism by which aP2 could
mediate its anti-atherosclerotic effects through modulating the UPR, helping to
clarify a much sought after but very challenging aspect of lipid chaperone biology
in macrophages and in atherosclerosis4,8. Finally, our findings offer tools to modulate
ER stress responses associated with dyslipidemia in vitro and
in vivo that may facilitate therapeutic applications including
that of aP2.Dramatic resistance to ER stress can be achieved by blocking aP2 action,
which is dependent on SCD-1 activity. aP2 prevents enrichment of macrophages in
desaturation products such as C16:1n7-palmitoleate, a molecule which provides relief
from lipid-induced ER stress, in addition to its other reported beneficial endocrine
effects34. It will be interesting to
determine whether C16:1n7 supplementation or a diet enriched with palmitoleate could
confer resistance to macrophage ER stress and reduction in atherosclerosis in future
studies. In this study, we showed that enhanced LXR–α
activity in aP2 macrophages
drives Fasn and SCD-1 transcription and resistance
to lipotoxic ER stress and identified the transcriptional mechanism underlying this
function of aP2. These observations also raise the possibility of a specific link
between the nuclear hormone receptor LXR–α and ER stress
responses. Overall, this study demonstrates that de novo fatty acid
synthesis and desaturation can be highly beneficial, if not essential, for defending
ER function when macrophages are exposed to toxic lipids. Accordingly, inhibition of
SCD-1 in the whole body may not have great therapeutic prospects due to adverse
metabolic effects seen in the macrophages and pancreatic β cells,
although elevated liver Δ9D activity has been linked to obesity and
diabetes10,44. Indeed, systemic inhibition of SCD-1 leads to severe
atherosclerosis despite protection from obesity and hepatosteatosis45. Similarly, activation of LXR in the whole
body leads to undesirable metabolic side effects, particularly in the liver. On the
other hand selective upregulation of LXR and SCD-1 activity in macrophages and
adipocytes, and downregulation in liver may be an optimal strategy and yield the
most beneficial overall metabolic outcome, including protection against diabetes and
atherosclerosis29.We unraveled a mechanism by which aP2 could mediate its anti-atherosclerotic
effects, at least in part, through modulating the UPR. It is important to note that
our findings do not exclude other LXR regulated macrophage responses as additional
contributors to aP2’s impact on macrophage function and atherosclerosis.
Since the most significant upregulation seen in the
aP2 macrophages is
that of SCD-1 and CD51 genes and knocking down
SCD-1 alone is sufficient to re-establish sensitivity to lipid-induced ER
dysfunction in the aP2
macrophages, LXR-mediated lipogenesis pathways are likely to dominate the
aP2-deficient phenotype related to lipotoxic ER stress. Yet, the impact of aP2 or
LXR on inflammatory functions of macrophages may also play a role in preventing
atherosclerosis. aP2 expression is limited to macrophages and dendritic cells in
normal conditions as well as in atherosclerotic lesions (Fig.2B and data not shown)10,22,46,47. While aP2 does
not alter antigen presentation, studies have shown that it can affect T cell priming
and cytokine production19,46,47.
Moreover, ER stress responses and inflammation are integrated at several levels and
modulate each other; inflammation can compromise ER function and ER stress can
promote inflammation10,. The links between
inflammatory pathways and ER stress are of great interest in chronic metabolic
disease and understanding the intricate links between lipid metabolism and the
immune system and identification of molecular targets like aP2 at this interface are
critical for developing effective therapeutics against the metabolic disease
cluster.In conclusion, we uncovered a previously unknown function for aP2 in
lipid-induced ER stress signaling in macrophages, while addressing the essential
role of ER stress in vascular disease progression (Fig.6g). The ability to defend against the lipids disrupting ER function
illustrates a novel metabolic adaptation capacity of macrophages that is governed by
the lipid chaperones. aP2 in particular, and perhaps cytosolic lipid chaperones in
general, could function as a molecular sensor for fatty acids and as a central
coordinator of metabolic-ER stress. Since aP2-deficiency can alleviate the ER stress
that occurs during atherosclerosis, similar to the actions of a chemical chaperone,
our findings offer insights into the detrimental role of macrophage ER stress in
atherosclerosis and the benefits of addressing this target to treat cardiovascular
disease.
MATERIALS AND METHODS
Mice, immunhistochemistry and quantification of arterial lesions
Colonies for
aP2 and
aP2mice on the C57BL/6 background were established in our facilities.
Nr1h3mice used
in this study were previously published40. Harvard Medical Area Standing Committee on Animals approved the
animal handling procedures. Mice were fed with Western diet for 16 weeks as
previously described29. After sacrifice,
aortas were flushed through the left ventricle and dissected as described
earlier29. To detect macrophages in
arterial lesions, 5µm serial cryosections of the proximal aorta were
fixed in acetone and incubated with antibodies following
manufacturer’s recommendations and previously established
protocols48. The sections were
incubated with biotinylated secondary antibodies and then with alkaline
phosphatase-labeled ABC (Vector Lab). Lesion areas were quantified using Imaging
System KS 300 (2.0; Kontron Electronik GmbH). For immunofluorescence stainings,
Alexa Fluor 488- and Alexa Fluor 647-conjugated secondary antibodies were
applied after an overnight incubation of the lesions with the primary antibody.
DAPI was used for counterstaining. The mean fluorescent intensity was measured
for each corresponding ER stress marker in the macrophage-dense areas using
Auxiovision 4.6 software (n≥3). For TUNEL analysis, serial the
sections were pretreated with 3% citric acid, fixed in
4% paraformaldehyde and stained using an in situ cell death
detection AP kit (Roche). After visualization of alkaline phosphatase with Fast
Red TR/Naphthol AS-NX substrate (Sigma), TUNEL-positive cells were counted (n=18
per aorta).
Analysis of serum lipids
Mice were fasted (4h) and the serum cholesterol and triglycerides were
measured by conventional enzymatic methods using the reagents from Raichem and
the SoftMax Pro5 software (Molecular Devices).
Quantitative real-time polymerase chain reaction (qRT-PCR) and immunoblot
analysis
RNA was isolated from macrophages using RNeasy kit (Qiagen), cDNA was
synthesized using iScript (Biorad) and qRT-PCR was performed using an ABI
Thermocycler. Macrophage proteins were harvested and total protein content was
assessed as previously described31. Equal
amounts of total protein per sample were subjected to SDS-PAGE and Western blots
were performed as described previously49.
Cell culture, knock-down, TUNEL, caspase and reporter assays
Unless otherwise indicated, bone-marrow derived mouse macrophage lines
were used. Reconstitution experiments were carried out in bone-marrow derived
macrophages that were immortalized29.
When indicated, peritoneal macrophages derived by 4% thioglycolate
elicitation were used. Macrophages were maintained in RPMI supplemented with
10% fetal bovine serum. For caspase 3/7 activity assays, cells were
plated on 96 well plates, and upon reaching confluency, treated with the
appropriate reagents to activate caspase activity over a time course. Caspase
3/7 activity was measured using the caspase 3/7-Glo kit (Promega) according to
the manufacturer’s instructions. For loss-of-function experiments,
siRNAs were transfected into 80% confluent macrophages using
sImporter (Upstate) according to the manufacturer’s instructions.
For reporter assays, macrophages plated on 12-well plates, grown to
80% confluency, and transfected with the appropriate plasmids using
Superfect (Qiagen). 24 hours post-transfection, cells were treated with LXR
ligands T0901317 (10µM) and 25 hydroxy cholesterol
(10µM), or DMSO followed by luciferase assays using the
Dual-Luciferase assays system (Promega) according to the
manufacturer’s instructions.
Lipidomics
Fatty acids (FA) were measured in 1 experiment (n=5) by Lipomics, Inc
(Sacramento, CA) in each neutral lipid class CE, DAG, PL, FFA and TG. The lipids
from plasma and tissues were extracted in the presence of authentic internal
standards by the method of Folch et al. using
chloroform:methanol (2:1 v/v). Individual lipid classes within each extract are
separated by liquid chromatography (Agilent Technologies model 1100 Series)34. Each lipid class was trans-esterified
in 1% sulfuric acid in methanol in a sealed vial under a nitrogen
atmosphere at 100 °C for 45 min. The resulting FA methyl esters were
extracted from the mixture with hexane containing 0.05% butylated
hydroxytoluene and prepared for gas chromatography by sealing the hexane
extracts under nitrogen. Fatty acid methyl esters were separated and quantified
by capillary gas chromatography (Agilent Technologies 6890) equipped with a 30 m
DB-88MS capillary column (Agilent Technologies) and a flame-ionization
detector.
Statistics
One-way ANOVA was used to determine significance in lesion size
differences. TUNEL assays: Statistical differences were
determined by one-way ANOVA multiple comparisons versus the control group
(Dunn’s method) in Fig.1 and.
the statistical differences in mean of TUNEL(+)/MOMA-2(+) lesion area between
the groups were determined by the Mann-Whitney rank sum test in Fig.3. Lipidomic analyses:
The distributions of each fatty acid within each lipid class were examined for
extreme outliers or poor measurement. If afatty acid was missing more than
30% of its observations, it was removed from further analysis.
Initial statistical analysis included a one-way ANOVA to identify fatty acids
within each lipid class that differed between the genotypes. Results of the
one-way ANOVA were visualized using lipid class composition analysis. Direct
comparisons between groups were made using a Wilcoxon rank test and visualized
using bar plots.
Authors: Laura L Listenberger; Xianlin Han; Sarah E Lewis; Sylvaine Cases; Robert V Farese; Daniel S Ory; Jean E Schaffer Journal: Proc Natl Acad Sci U S A Date: 2003-03-10 Impact factor: 11.205
Authors: Sean B Joseph; Bryan A Laffitte; Parthive H Patel; Michael A Watson; Karen E Matsukuma; Robert Walczak; Jon L Collins; Timothy F Osborne; Peter Tontonoz Journal: J Biol Chem Date: 2002-01-14 Impact factor: 5.157
Authors: J J Repa; S D Turley; J A Lobaccaro; J Medina; L Li; K Lustig; B Shan; R A Heyman; J M Dietschy; D J Mangelsdorf Journal: Science Date: 2000-09-01 Impact factor: 47.728
Authors: Liza Makowski; Jeffrey B Boord; Kazuhisa Maeda; Vladimir R Babaev; K Teoman Uysal; Maureen A Morgan; Rex A Parker; Jill Suttles; Sergio Fazio; Gökhan S Hotamisligil; MacRae F Linton Journal: Nat Med Date: 2001-06 Impact factor: 53.440
Authors: F Enrique Gomez; Makoto Miyazaki; Young-Cheul Kim; Padma Marwah; Henry A Lardy; James M Ntambi; Brian G Fox Journal: Biochemistry Date: 2002-04-30 Impact factor: 3.162
Authors: Margaret F Gregor; Ling Yang; Elisa Fabbrini; B Selma Mohammed; J Christopher Eagon; Gökhan S Hotamisligil; Samuel Klein Journal: Diabetes Date: 2008-12-09 Impact factor: 9.461
Authors: Tracie A Seimon; Marissa J Nadolski; Xianghai Liao; Jorge Magallon; Matthew Nguyen; Nicole T Feric; Marlys L Koschinsky; Richard Harkewicz; Joseph L Witztum; Sotirios Tsimikas; Douglas Golenbock; Kathryn J Moore; Ira Tabas Journal: Cell Metab Date: 2010-11-03 Impact factor: 27.287
Authors: Vladimir R Babaev; Richard R Whitesell; Liying Li; MacRae F Linton; Sergio Fazio; James M May Journal: Free Radic Biol Med Date: 2010-10-23 Impact factor: 7.376
Authors: Timo D Müller; Sang Jun Lee; Martin Jastroch; Dhiraj Kabra; Kerstin Stemmer; Michaela Aichler; Bill Abplanalp; Gayathri Ananthakrishnan; Nakul Bhardwaj; Sheila Collins; Senad Divanovic; Max Endele; Brian Finan; Yuanqing Gao; Kirk M Habegger; Jazzmin Hembree; Kristy M Heppner; Susanna Hofmann; Jenna Holland; Daniela Küchler; Maria Kutschke; Radha Krishna; Maarit Lehti; Rebecca Oelkrug; Nickki Ottaway; Diego Perez-Tilve; Christine Raver; Axel K Walch; Sonja C Schriever; John Speakman; Yu-Hua Tseng; Maria Diaz-Meco; Paul T Pfluger; Jorge Moscat; Matthias H Tschöp Journal: J Clin Invest Date: 2012-12-21 Impact factor: 14.808
Authors: Shaikh M Rahman; Rachel C Janssen; Mahua Choudhury; Karalee C Baquero; Rebecca M Aikens; Becky A de la Houssaye; Jacob E Friedman Journal: J Biol Chem Date: 2012-08-19 Impact factor: 5.157